ASH 2022 Conference Coverage
ASH 2022 Phase 1/2 LINKER-MM1 Study of Linvoseltamab, a BCMAxCD3 Bispecific Antibody, for the Treatment of R/R MM: Updated Safety and Efficacy
By
ASH 2022 Conference Coverage
FEATURING
Naresh Bumma
By
ASH 2022 Conference Coverage
FEATURING
Naresh Bumma
Login to view comments.
Click here to Login